BridgeBio Pharma's Beyonttra to treat transthyretin─mediated amyloid cardiomyopathy receives Japanese approval
BridgeBio Pharma, Inc., a new type of biopharmaceutical company focused on genetic diseases, announced the Japanese Ministry of Health, Labour and Welfare has approved acoramidis, under the brand name Beyonttra, for the treatment of adults with …